Member Info for Thelix

Nice drop here. Rise coming soon personally after this. I am in longterm. Was sitting at 4p a month ago so not really concerned at 6.4p

we have our first deramper come through. This has already risen by 80%. Not sure what you mean by your 4% nonsense, and this certainly wont nosedive red. If it does - it will soon recover. Very happy with my holding here and made a mint going from 4-5p to 12p last time and am fully expecting similar rise here to 25p or more. The directors options activate at 10, 20 and 50p. Directors will align their options with what they percieve as doable performances. 50p will put the mcap to a poultry figure given the nature of this business and the consumer market being worth dozens of multiples more than the 50p options activating. All we need is a commercial partner really and when that happens we have lift off.

Nah was me topping up....I wish! Lol. This was my only blue share today. Brutal day for the markets so much dropped.

Expecting a commercial partner RNS very soon. I am very excited a out OXP. Jave loaded up nicely at 6p many months back and will sit on this nicely. Have been tempted to throw another few k at it but I never like too heavily in one company. Eggs and baskets and all that jazz.

It will recover soon. This is only going one way and it is going to be pretty big. Unless a real spanner hits us that is impossible to know right now this should easily hit 25p and stretch to 30-35p on a good RNS. IMHO

That includes downwards. Weve had this ratio of buys sells with an 11% blue day. Just the buys and sells are inverted so we get an 11% red. Nothing moves in a constant upward trend. Should recover soon.

The share did this to 13p before too without RNS's but a few. Small freefloat. Moves on tiny volume. Oh and H2 should see some commercialisation RNS's. Happy days personally. Glad I rode the rollercoaster twice so to speak. Have loaded up very heavily here a few months back @6p because I am fully expectig 25p+.

With massive % increases. 1 commercial/partner/royalty RNS and this will go stratospheric. Hold on tight.

This has always moved on tiny volume. It went from 6p to 4p for a few mil share sales. In @ 6p. Already made a mint on the last run from 4-5p to 12p. Round 2. This time though 25p+. Nice 5 bagger for me here ainreckon. Would love 50p but might be a while for that

Some were available at 10p and they didn't sell, so the BOD are bullish they can get more money from their shares if they're patient enough. This share always went up and down fast on little volume. Such a small freefloat. With another positive trial RNS this will start its rerate again.

Trial results are fantastic and all, but regulatory know-how and approval and continued quality from the company is a commercial requirement. The fact the MHRA have been involved means we're close to commercial goals. This moves on little volume so will be nice to start seeing 6-8p again.

To be fair, they're simply in partnering discussions. No deals have been made. Any and every company on the market worldwide can have partnering discussions. It is when those talks become immediately more apparent or further along that the tick ups will begin.

to see what this news brings. In @ 6p. Never expected it to go into the 4's, but oh well. This will be the 2nd bounce I am hoping to get from OXP. Have good hopes for this getting to 20p within reasonable time-frames. Just need those clinical trial results to come through golden.

Also in this worlds current economic climate, health regulators and pricing committees are going to prefer the tried and tested oral route for a decent price over a fancy polymer patch that will cost a lot more. Pricing really is one major hurdle people forget about. Your drug can pass everything, but if the authorities do not want to buy your product for an obscene price, they don't have to. This is why people protest the NHS as they don't always make every drug available which is in other countries, and this is because NICE sometimes say "too expensive for the benefit seen". I really wouldn't worry about those patches. Also they would only work on localised pain. Our product is still the best all rounder while removing many of the nasty side effects.

That nurofen issue has been known for years, just takes a while for the courts to do something about it. All 4 products do work on those 4 symptoms (headaches, backaches, period pain etc). The issue is that same product has different prices. That was the issue. They were purposefully marking up a product for one problem which had the same active ingredient as the other. That is a big no no in pharma industry. It does not change the actual medical benefits of ibuprofen. secondly - this patch which has everyone up in a tissy. It is a university prototype patch. It is years away from even being in trials, let alone commercialisation, some reality checks needed here please. Oxford Pharma is well on the way to signing up with commercial partners in 2016 from what the RNS's seem to say. Fantastic buying opportunity and have loaded up quite a bit here with these prices. One product just slightly fails a trial, a University makes a patch that's years away from completion and the price goes from 13p to 4.8p? lol. Massive over-reaction. OXP still has success in the other compounds in trials and will reformulate for the failed one. It failed by only a small amount - retrial with better formulation should easily work. I am surprised it has dipped this low, but the uprise should begin shortly. On a side note, the AIM this week has taken a massive hammering. I have a massive watchlist that I am interested in for the future and they've all been quite red (good buying opportunity on some of them I guess).

"I looked at the cash position and concluded that given yesterday's news, it is more likely some commercial deal will be reached on OXPzero ibuprofen before the cash runs out, so I'm happy with where we are" ^^ This, I am in agreement with.

No offence intended, but no, £20 million as of last placing is not cash for 5 years within the pharmaceutical sector. For a start - it depends entirely on the rate of expansion and trials, and if any bumps are along the way, and secondly, within the next 2 odd years I would hope OXP achieves a financial partner of sorts that is interested in the formulations. Usually smaller companies are snapped up by bigger ones, or the patents bought out. Take it from someone in the Pharma sector - £20 million is not a lot of cash, and can be spent very quickly and easily on trials and studies. This isn't me being negative, I am invested in OXP and am very bullish of it. But you pulled 5 years worth of funds out your posterior there.

Only caution is the naproxen did not achieve statistically significant lanza scoring. Ibuprofen works fine - which already gives us a product and an income. The lanza scoring didn't miss the signifiance by a longshot - the company is confident it can reformulate and succeed. It's not as if the scores were absolutely dreadful - from what I understand. Woodford has a "large holding" in comparison to PI's, however his entire portfolio OXP doesn't each attain a percentile from my knowledge. While it is promising to have sticky ii money, it does not make the share infallible. I managed to get my basement 6p prices as I wanted about 1.5 months ago when it was hovering 6.5-6.75p and trickled down. Very excited over the next few months. This should bounce to 10p very quickly - and potentially meet resistance depending on the news that comes out.

much further. I will be absolutely flabberghasted if this dips into the 5's. Should start to see some recovery soon, though without a positive RNS might see lower 6's.

lol Woodford does not control the company. So institutional investors never, ever, ever get it wrong? Short term pain, long term gain. The slightly below statistically significant data has given many an excellent buying opportunity. This will recover.